AZD0901 vs. Other Treatments in Gastric Cancer
Phase 3
572
about 2.5 years
18–130
38 sites in AL, AZ, CA +16
What this study is about
This trial is testing AZD0901 compared to other treatments for people with advanced or metastatic gastric cancer that expresses CLDN18.2. The goal is to see if AZD0901 is effective and safe as a treatment option.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take AZD0901
- 2.Take Apatinib
- 3.Take Docetaxel
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
kinase inhibitor, docetaxel, irinotecan, ramucirumab, paclitaxel (Taxane chemotherapy; stabilizes microtubules)
infusion, injection (Injection), injection, intravenous
Primary: Overall Survival (OS) for 3L+ participants, Progression Free Survival (PFS) in all randomized participants
Secondary: Duration of Response (DoR) in all randomized participants, Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]. Changes from baseline in vital signs, clinical laboratory results, and ECGs, ORR for 3L+ participants, OS in all randomized participants, Objective Response Rate (ORR) in all randomized participants, PFS for 3L+ participants, PK parameters (such as peak concentration, as data allow) of AZD0901, total antibody and MMAE, PK parameters (such as trough concentration, as data allow) of AZD0901, total antibody and MMAE